Evotec has partnered Bristol-Myers Squibb to launch another Bridge programme, this time focusing on the universities of Birmingham, Dundee, Edinburgh and Nottingham.

The universities of Birmingham, Dundee, Edinburgh and Nottingham have joined forces with drug discovery firm Evotec and pharmaceutical firm Bristol-Myers Squibb to launch BeLab1407.
Equipped with $20m, BeLab1407 is the latest addition to Evotec’s international network of early-stage academic collaborations called Bridge – an acronym for Biomedical Research, Innovation and Development Generation Efficiency. It will focus on drug discovery.
Bridge was launched in 2016 through Lab282 at University of Oxford, with $16m of capital. The institution subsequently…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in